Get the Stockscreener App
1.78
10.55%
-0.21
After Hours:
1.82
0.04
+2.25%
Gain Therapeutics Inc stock is traded at $1.78, with a volume of 608.85K.
It is down -10.55% in the last 24 hours and up +63.30% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
See More
Previous Close:
$1.99
Open:
$1.99
24h Volume:
608.85K
Relative Volume:
1.71
Market Cap:
$48.53M
Revenue:
$210.70K
Net Income/Loss:
$-22.22M
P/E Ratio:
-0.978
EPS:
-1.82
Net Cash Flow:
$-17.13M
1W Performance:
+14.84%
1M Performance:
+63.30%
6M Performance:
-52.79%
1Y Performance:
-45.73%
1-Day Range:
$1.63
$1.99
1-Week Range:
$1.538
$2.00
52-Week Range:
$0.89
$5.33
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - The Manila Times
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s - The Bakersfield Californian
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - StockTitan
Understanding the Risks of Investing in Gain Therapeutics Inc (GANX) - Knox Daily
Nuvation Bio Inc [NUVB] Investment Appeal on the Rise - Knox Daily
Gain Therapeutics Inc [NASDAQ: GANX] Sees Increase in Stock Value - Knox Daily
Gain Therapeutics Inc (GANX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease - The Manila Times
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming - The Bakersfield Californian
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease - StockTitan
Can you still get a good price for Perspective Therapeutics Inc (CATX) Shares at this point? - US Post News
Can you still get a good price for Black Diamond Therapeutics Inc (BDTX) Shares at this point? - US Post News
Gaining Ground: BioXcel Therapeutics Inc (BTAI) Closes Lower at 0.58, Down -12.13 - The Dwinnex
Retail investors who hold 56% of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) gained 13%, institutions profited as well - Simply Wall St
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024 - StockTitan
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year? - Yahoo Finance
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday - Benzinga
Investing in Sarepta Therapeutics (NASDAQ:SRPT) five years ago would have delivered you a 55% gain - Simply Wall St
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Gaining Ground: CytomX Therapeutics Inc (CTMX) Closes Lower at 1.23, Down -1.60 - The Dwinnex
Daily Market Movement: Spyre Therapeutics Inc. (SYRE) Sees a 3.23 Increase, Closing at 29.36 - The Dwinnex
Retail investors who hold 48% of Candel Therapeutics, Inc. (NASDAQ:CADL) gained 14%, insiders profited as well - Simply Wall St
Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why - MSN
Gain Therapeutics Inc (GANX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Solventum Shares May Gain on the Launch of Its New V.A.C Therapy - Yahoo Finance
Gain Therapeutics Inc (GANX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Daily Market Movement: Apogee Therapeutics Inc. (APGE) Sees a 0.55 Increase, Closing at 47.51 - The Dwinnex
Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why - Yahoo Finance
Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher - Benzinga
Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex
Market Watch: Verve Therapeutics Inc (VERV)’s Noteworthy Gain, Closing at 5.59 - The Dwinnex
Gain Therapeutics Initiates $50 million equity distribution - Investing.com
Cullinan Therapeutics Inc (CGEM) stock analysis: A comprehensive overview - US Post News
Gain Therapeutics’ (GANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BTIG maintains Buy rating on Gain Therapeutics shares By Investing.com - Investing.com Canada
Gain Therapeutics shares hold steady price target and Buy rating on clinical trial - Investing.com Canada
What is the investor’s view on Nurix Therapeutics Inc (NRIX)? - US Post News
Gain Therapeutics shares hold steady price target and Buy rating on clinical trial - Investing.com UK
It would be worthwhile to take a closer look at Gain Therapeutics Inc (GANX) - US Post News
Gain readies for Phase 1b trial of Parkinson’s therapy GT-02287 - Parkinson's News Today
Gaining Ground: Sangamo Therapeutics Inc (SGMO) Closes Higher at 0.85, Up 2.78 - The Dwinnex
Recent Insider Activity Could Benefit Gain Therapeutics Inc (GANX) - Knox Daily
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Can you still get a good price for Aptevo Therapeutics Inc (APVO) Shares at this point? - US Post News
Daily Market Movement: Dermata Therapeutics Inc (DRMA) Sees a 1.16 Increase, Closing at 1.74 - The Dwinnex
Can you now get a good deal on Carisma Therapeutics Inc’s shares? - US Post News
Digital Therapeutics and Wellness Market is Projected to Increase at a Strong CAGR of 14.6% by 2033 | Future Market Insights, Inc. – Market Research Blog - Market Research Blog
What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You - Simply Wall St
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):